At the committee’s recommendation, the primary e
Post# of 148160
Read More: https://investorshangout.com/post/view?id=584...z6UDhhzGpI
Wouldn't a similar change in our phase 3 endpoint also highlight leronlimab's ability to calm the chemokine storm in our stage 2- m/m trial thereby preventing lung and liver damages?
What do you think Ohms?